Medically reviewed by Marla Anderson, MD Multiple myeloma is a rare blood cancer that develops in the plasma cells, which are ...

Bispecific antibodies have altered the multiple myeloma (MM) treatment landscape, but some practices still lack enough familiarity with these therapeutics to deliver them in outpatient settings.

The publication of the pricing and reimbursement decision for Pepaxti (melflufen) in the Gazetta Ufficiale removes the last ...

Paris: Following the adoption of a positive opinion by the European Medicines Agency's (EMA) Committee for Medicinal Products ...

So there are multiple sort of ways of targeting ... say we also are seeing the development of bispecific antibodies in general in myeloma. And we have so far three approved products to use ...

In this article, Cerba dives into CAR+ T-cell therapy, from patient treatment to solutions for minimal residual disease (MRD) ...

Oncopeptides AB (publ), a biotech company focused on difficult-to-treat cancers, today announces that the positive reimbursement decision for its drug Pepaxti (melflufen) has been published in the ...

one of two much-anticipated bispecific antibodies the drugmaker has developed for patients with multiple myeloma. The double-headed antibody binds to CD3 on T cells and redirects them to BCMA ...

H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on Genmab (GMAB – Research Report) today and set a price target of $50.00.Invest ...